Herantis Pharma’s Annual Report 2019 published
Herantis Pharma Plc
Company release 17 March 2020 at 9:00 am Eastern European Time
Herantis Pharma Plc’s Annual Report for the year 2019 has been published today. The Annual Report contains financial statements and the report of the Board of Directors. The Annual Report is available in PDF format in Finnish and English as an appendix to this release and on the company’s web site at http://herantis.com in section Investors – Financial information.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +46 72 888 43 83
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland with ticker symbol ‘HRTIS’ and Nasdaq First North Growth Market Sweden with ticker symbol ‘HRNTS’.